US 12,312,341 B2
Methods for treating cancer
David St. Jean, Jr., Natick, MA (US)
Assigned to Scorpion Therapeutics, Inc., Indianapolis, IN (US)
Filed by Scorpion Therapeutics, Inc., Boston, MA (US)
Filed on Aug. 6, 2024, as Appl. No. 18/795,384.
Application 18/795,384 is a continuation of application No. 18/509,967, filed on Nov. 15, 2023, granted, now 12,084,434.
Application 18/509,967 is a continuation of application No. 18/450,586, filed on Aug. 16, 2023, granted, now 11,897,871, issued on Feb. 13, 2024.
Application 18/450,586 is a continuation of application No. PCT/US2022/033255, filed on Jun. 13, 2022.
Claims priority of provisional application 63/348,261, filed on Jun. 2, 2022.
Claims priority of provisional application 63/319,236, filed on Mar. 11, 2022.
Claims priority of provisional application 63/316,017, filed on Mar. 3, 2022.
Claims priority of provisional application 63/288,909, filed on Dec. 13, 2021.
Claims priority of provisional application 63/228,351, filed on Aug. 2, 2021.
Claims priority of provisional application 63/210,370, filed on Jun. 14, 2021.
Prior Publication US 2024/0400543 A1, Dec. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 405/12 (2006.01); A61K 31/343 (2006.01); A61K 31/381 (2006.01); A61K 31/382 (2006.01); A61K 31/4035 (2006.01); A61K 31/416 (2006.01); A61K 31/427 (2006.01); A61K 31/437 (2006.01); A61K 31/443 (2006.01); A61K 31/4525 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/5386 (2006.01); A61K 31/541 (2006.01); C07D 307/81 (2006.01); C07D 307/83 (2006.01); C07D 403/12 (2006.01); C07D 405/14 (2006.01); C07D 409/12 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 491/107 (2006.01); C07D 498/10 (2006.01)
CPC C07D 405/12 (2013.01) [A61K 31/343 (2013.01); A61K 31/381 (2013.01); A61K 31/382 (2013.01); A61K 31/4035 (2013.01); A61K 31/416 (2013.01); A61K 31/427 (2013.01); A61K 31/437 (2013.01); A61K 31/443 (2013.01); A61K 31/4525 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/5386 (2013.01); A61K 31/541 (2013.01); C07D 307/81 (2013.01); C07D 307/83 (2013.01); C07D 403/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 491/107 (2013.01); C07D 498/10 (2013.01)] 16 Claims
 
1. A method of treating an endometrial cancer in a human subject, the endometrial cancer having one or more mutations in PI3Kα, the method comprising administering to the subject a therapeutically effective amount of a compound which is 1-(2-aminopyrimidin-5-yl)-3-(1-(5,7-difluoro-3-methylbenzofuran-2-yl)-2,2,2-trifluoroethyl) urea, or a pharmaceutically acceptable salt thereof, having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.